Octapharma
Octapharma AG, founded in 1983, is a family-owned pharmaceutical company, and bills itself as "one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines[3]."
 | |
| Type | Private |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 1983 |
| Headquarters | , |
Number of locations | 31 |
| Products | octanate; octanine-F; wilate; Nuwiq; octagam; gammanorm; rhesonativ; panzyga; albunorm; octaplas; atenativ; octaplex; octaplasLG; fibryga See complete products listing. |
| Revenue | Euro 2.5 billion (2021)[1] |
Number of employees | 9,977(2021)[2] |
| Website | www.octapharma.com |
Therapeutic Areas
Patients in 118 countries are treated with products in the following therapeutic areas:
- Haematology: high-purity coagulation factor concentrates for patients with bleeding disorders Haemophilia A, B and von Willebrand Disease.
- Immunotherapy: immunomodulation or immunoglobulin replacement therapy for the treatment of immune-mediated diseases and deficiencies (immune disorders including autoimmune diseases and antibody deficiency) by inducing, enhancing, or suppressing an immune response.
- Critical Care: human plasma and protein products for treating critically ill or injured patients in intensive care and emergency medicine settings.[3]
History
Octapharma was founded in 1983. In the name Octapharma, the “octa” is derived from the Greek word for eight, named after the factor which is deficient in haemophilia A patients. Octapharma's inaugural product was the first Factor VIII concentrate using what was then innovative solvent detergent virus inactivation technology.
The underlying principle of Octapharma's R&D is the development of therapies based on human proteins either purified from human plasma or produced by recombinant technologies applied to human cell lines.
Products
Octapharma medicines treat a broad range of rare and life-threatening congenital and acquired diseases and conditions:
- bleeding disorders (hemophilia A / B and VWD) - over 300 types of primary and secondary immune deficiencies - numerous auto-immune and neurological disorders - acute conditions - critical care issues (including trauma and burn victims) - cancer patients - major surgeries - protection of new-borns in case of Rh negative pregnancies
Production
Octapharma converts source plasma into plasma protein products through fractionation and processing. Each therapy created is controlled, fractionated, purified, virus-inactivated and inspected before being used.
As of December 31, 2021, Octapharma employs around 10,000 people worldwide. The company has seven R&D sites, five manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 180 plasma donation centres across Europe and the US.
Notes and references
External links
